كما أشرت من قبل من موقع مراكز التحكم والوقاية من الأمراض أنهم لم يتأكدوا من مدة فاعلية التطعيم ( الآن فايزر تقر بعد 4 أو 6 شهور تقل المناعة لمن تعاطوا الجرعتين!!) وقد يحتاج إلى جرعة تنشيطية لم يقر بعد

The effectiveness of Pfizer’s COVID-19 shot can drop to 83.7% within four to six months after getting the second dose of its vaccine. This is the latest indication that vaccine-induced immunity to the virus can wane and some kind of boost may be necessary in the future.

New research published Wednesday as a preprint indicates that the Pfizer Inc. PFE, 0.35% shot provides 96.2% protection for the first two months, 90.1% effectiveness between the second and fourth months, and between 83.7% of protection for the fourth, fifth, and six months. 

“We will need a booster eight to 12 months from the second dose,” Pfizer CEO Albert Bourla said Wednesday, according to a FactSet transcript of the company’s second-quarter earnings call. 

The drug maker has been making the case for booster shots, citing limited data from its own clinical research and real-world data out of Israel, where Pfizer’s vaccine is the predominant shot in circulation. 

“We do see—after six to eight months—more rapid waning concerning infections and mild to moderate symptoms,” Dr. Mikhail Dolsten, Pfizer’s chief scientific officer, said during the call. “Those are likely entirely, or to a large degree, dependent on antibodies and the drop in titer that we alluded to. If you raise it, you may have a good probability to reverse that waning.”

Still, there’s no simple black-and-white answer to whether booster shots are needed at this time. 

One, there is no definitive data. The new Pfizer data is the most detailed so far, though the company plans to submit clinical data for a third dose to the Food and Drug Administration in early August.

When speaking to investors this week, company officials attributed waning immunity levels in Israel to the much earlier vaccination campaign that rolled out in that country. (In fact, Israel announced Thursday that a third dose will now be available to people who are at least 60.) Pfizer also mentioned that there will be data in a few months coming out of the U.K., where doses were sometimes spaced out, that indicates “long-lasting protection.”

In addition, we still don’t know which people will need to boost their protection levels. Will the entire vaccinated population need a boost? What if third shots are only necessary for the elderly or people who are immunocompromised? What diagnostic test can be used to assess titer levels before giving a booster? How soon does this all need to happen? 

“While I cannot predict with certainty the future, I would not be surprised if, similar to flu, that we would need…to boost our vaccine against COVID,” Dolsten said. “Whether this will be on an annual [basis] or based on simple diagnostics that allow it to be boosted at the right time before your risk for infection is high, we need to monitor.” 

Either way, it’s a boon for Pfizer, as the legacy drug maker shifts into its new role as a vaccine leader.

Pfizer is expected to generate $33.5 billion in COVID-19 vaccine revenue this year, and Wall Street analysts have already baked boosters into their financial models for Pfizer and BioNTech SE BNTX, 1.79%, which developed the vaccine with Pfizer. 

“The largest remaining uncertainty is whether this third boost is simply the third dose in a three-vaccine schedule to achieve lasting, broad protection or is the first of a periodic (annual) boosted vaccine,” SVB Leerink analysts told investors on Thursday. 

Moderna Inc. MRNA, 2.87%, which developed the other FDA-authorized mRNA-based COVID-19 vaccine, is also testing booster shots in clinical trials. It has been much quieter in its communication around a third shot. The company is scheduled to share second-quarter earnings on Aug. 5.

Pfizer’s stock is up 16.3% so far this year, while the broader S&P 500 SPX, -0.49% has gained 17.1%.

المصدر : https://www.marketwatch.com/story/pfizer-says-immunity-drops-to-83-within-six-months-in-people-who-got-its-covid-19-shot-further-bolstering-the-company-case-for-a-booster-11627579817?siteid=yhoof2 

القصيدة النونية المؤلف: لعله أبو عبد الله محمد بن صالح القحطاني، المعافري الأندلسي المالكي

يا منزل الآيات والفرقان ... بيني وبينك حرمة القرآن

اشرح به صدري لمعرفة الهدى ... واعصم به قلبي من الشيطان

يسر به أمري وأقض مآربي ... وأجر به جسدي من النيران

واحطط به وزري وأخلص نيتي ... واشدد به أزري وأصلح شأني

واكشف به ضري وحقق توبتي ... واربح به بيعي بلا خسراني

طهر به قلبي وصف سريرتي ... أجمل به ذكري واعل مكاني

واقطع به طمعي وشرف همتي ... كثر به ورعي واحي جناني

أسهر به ليلي وأظم جوارحي ... أسبل بفيض دموعها أجفاني

أمزجه يا رب بلحمي مع دمي ... واغسل به قلبي من الأضغاني

أنت الذي صورتني وخلقتني ... وهديتني لشرائع الإيمان

أنت الذي علمتني ورحمتني ... وجعلت صدري واعي القرآن

أنت الذي أطعمتني وسقيتني ... من غير كسب يد ولا دكان

وجبرتني وسترتني ونصرتني ... وغمرتني بالفضل والإحسان

أنت الذي آويتني وحبوتني ... وهديتني من حيرة الخذلان

وزرعت لي بين القلوب مودة ... والعطف منك برحمة وحنان

ونشرت لي في العالمين محاسنا ... وسترت عن أبصارهم عصياني

وجعلت ذكري في البرية شائعا ... حتى جعلت جميعهم إخواني

والله لو علموا قبيح سريرتي ... لأبى السلام علي من يلقاني

ولأعرضوا عني وملوا صحبتي ... ولبؤت بعد كرامة بهوان

لكن سترت معايبي ومثالبي ... وحلمت عن سقطي وعن طغياني

فلك المحامد والمدائح كلها ... بخواطري وجوارحي ولساني

ولقد مننت علي رب بأنعم ... مالي بشكر أقلهن يدان

فوحق حكمتك التي آتيتني ... حتى شددت بنورها برهاني

لئن اجتبتني من رضاك معونة ... حتى تقوي أيدها إيماني

لأسبحنك بكرة وعشية ... ولتخدمنك في الدجى أركاني

ولأذكرنك قائما أو قاعدا ... ولأشكرنك سائر الأحيان

ولأكتمن عن البرية خلتي ... ولاشكون إليك جهد زماني

ولأقصدنك في جميع حوائجي ... من دون قصد فلانة وفلان

ولأحسمن عن الأنام مطامعي ... بحسام يأس لم تشبه بناني 

ولأجعلن رضاك أكبر همتي ... ولأضربن من الهوى شيطاني

ولأكسون عيوب نفسي بالتقى ... ولأقبضن عن الفجور عناني

ولأمنعن النفس عن شهواتها ... ولأجعلن الزهد من أعواني

ولأتلون حروف وحيك في الدجى ... ولأحرقن بنوره شيطاني

من روائع أبو العتاهية

يا نَفسُ قَد أَزِفَ الرَحيلُ

وَأَظَلَّكِ الخَطبُ الجَليلُ

فَتَأَهَّبي يا نَفسِ لا

يَلعَب بِكِ الأَمَلُ الطَويلُ

فَلَتَنزِلِنَّ بِمَنزِلٍ

يَنسى الخَليلَ بِهِ الخَليلُ

وَلَيَركَبَنَّ عَلَيكِ في

هِ مِنَ الثَرى ثِقلٌ ثَقيلُ

قُرِنَ الفَناءُ بِنا فَما

يَبقى العَزيزُ وَلا الذَليلُ

لا تَعمُرِ الدُنيا فَلَي

سَ إِلى البَقاءِ بِها سَبيلُ

يا صاحِبَ الدُنيا أَبِالدُ

نيا تُدِلُّ وَتَستَطيلُ

كُلٌّ يُفارِقُ روحَهُ

وَبِصَدرِهِ مِنها غَليلُ

عَمّا قَليلٍ يا أَخا الشَهَو

اتِ أَنتَ لَها قَتيلُ

فَإِذا اِقتَضاكَ المَوتُ نَفسَ

كَ كُنتَ مِمَّن لايُحيلُ

فَهُناكَ مالَكَ ثَمَّ إِل

لا فِعلُكَ الحَسَنُ الجَميلُ

إِنّي أُعيذُكَ أَن يَمي

لَ بِكَ الهَوى فيمَن يَميلُ

وَالمَوتُ آخِرُ عِلَّةٍ

يَعتَلُّها البَدَنُ العَليلُ

لِدِفاعِ دائِرَةِ الرَدى

يَتَضايَقُ الرَأيُ الأَصيلُ

فَلَرُبَّما عَثَرَ الجَوا

دُ وَرُبَّما حارَ الدَليلُ

وَلَرُبَّ جيلٍ قَد مَضى

يَتلوهُ بَعدَ الجيلِ جيلُ

وَلَرُبَّ باكِيَةٍ عَلَيَّ

غَنائُها عَنّي قَليلُ

Heart rate from express.co.uk

Resting heart rate chart by age:

HEART RATE is a crucial indicator of how our hearts are working. So what should your resting heart rate be and how can you check it?

Our heart has a big role to play in the day-to-day functioning of our bodies, as it is responsible for pumping blood and oxygen. When looking after our cardiovascular health, it is important to pay attention to our heart rate. Resting heart rate is the number of times the heart beats each minute when someone isn't active. It is easy to work out what your resting heart rate is, so read on to find out more.

What should resting heart rate be?

Most adults have a resting heart rate between 60 and 100bpm, according to the NHS.

However, the fitter someone is, the lower their resting heart rate is likely to be.

The NHS website adds: "See a GP to get checked if you think your heart rate is continuously above 120bpm or below 40bpm, although it may simply be that this is normal for you."

Normal resting heart rates differ for children and are as follows, according to Medical News Today:

· Up to 1 month - 70 to 190 beats per minute (bpm)

· From 1 to 11 months - 80 to 160 bpm

· From 1 to 2 years - 80 to 130 bpm

· From 3 to 4 years - 80 to 120 bpm

· From 5 to 6 years - 75 to 115 bpm

· From 7 to 9 years - 70 to 110 bpm

· Over 10 years - 60 to 100 bpm



How can you check your resting heart rate?

Resting heart rate is measured by counting the number of times the heart beats while sitting still. To check your resting heart rate, you can use a heart rate monitor or alternatively check your pulse. To do this, the British Heart Foundation (BHF) explains you can put one of our hands out so you are looking at your palm. Place the pads of your first two fingers of the other hand on the inside of the wrist, at the base of the thumb, and press lightly.










If you can't feel your pulse, press slightly harder and check for about 30 seconds to see if it feels regular or not.

Count the number of beats after 60 seconds, or count the beats for six seconds and multiply by 10, to find out your resting heart rate in beats per minute (bpm).

The BHF explains that if your pulse feels irregular, check it for the full 60 seconds.

An irregular heart rhythm or pulse or any other concerns should be checked with a doctor, to check whether it is indicative of a health problem like arrhythmia.

What should your target heart rate be by age?

In general, maximum heart rate depends on age and one way to work it out is to take your age away from 220.

Target heart rate is usually between 50 and 70 percent of someone's maximum heart rate for moderate exercise intensity.

In general, the BHF says people should aim to exercise with their heart rate between these two figures.

But everyone's circumstances are different and for anyone with a heart condition it is important to check with a doctor before doing any new exercises.

Here is a chart of target heart rates based on age, as per the American Heart Association:

Age: 20 years
Target HR Zone 50-85%: 100-170 bpm
Average Maximum Heart Rate, 100%: 200 bpm

Age: 30 years
Target HR Zone 50-85%: 95-162 bpm
Average Maximum Heart Rate, 100%: 190 bpm

Age: 35 years
Target HR Zone 50-85%: 93-157 bpm
Average Maximum Heart Rate, 100%: 185 bpm

Age: 40 years
Target HR Zone 50-85%: 90-153 bpm
Average Maximum Heart Rate, 100%: 180 bpm

Age: 45 years
Target HR Zone 50-85%: 88-149 bpm
Average Maximum Heart Rate, 100%: 175 bpm

Age: 50 years
Target HR Zone 50-85%: 85-145 bpm
Average Maximum Heart Rate, 100%: 170 bpm

Age: 55 years
Target HR Zone 50-85%: 83-140 bpm
Average Maximum Heart Rate, 100%: 165 bpm

Age: 60 years
Target HR Zone 50-85%: 80-136 bpm
Average Maximum Heart Rate, 100%: 160 bpm

Age: 65 years
Target HR Zone 50-85%: 78-132 bpm
Average Maximum Heart Rate, 100%: 155 bpm

Age: 70 years
Target HR Zone 50-85%: 75-128 bpm
Average Maximum Heart Rate, 100%: 150 bpm

Blood pressure from express.co.uk

Blood pressure chart: What is a healthy range? 8 signs your blood pressure is too high

BLOOD PRESSURE measures the force that your heart uses to pump blood around the body, but can be dangerous if gets too high or drops too low. So, what is a healthy blood pressure range?

Blood pressure, when too high, is often related to unhealthy lifestyle habits like drinking too much alcohol, smoking cigarettes, eating unhealthy foods, being overweight and not doing enough physical exercise. When it’s left untreated, high blood pressure can seriously drive up your risk of developing numerous long-term health conditions, like coronary heart disease and kidney disease. Low blood pressure is much less common, and is sometimes brought on by medicinal side effects.

What is a healthy blood pressure range?

Blood pressure is the pressure of the blood within the human arteries and is produced primarily by the heart muscles contracting.

Blood pressure is measured using two recorded numbers.

The first looks at systolic pressure and is measured after the heart contracts at its highest level.

The second, called diastolic pressure, is measured before the heart contracts at its lowest, while blood pressure elevation is referred to as hypertension.

Blood pressure can be categorised into five different kinds in an effort to distinguish what’s high.

Normal blood pressure below 120/80 mm Hg is considered to be a healthy level all around.

Elevated blood pressure readings consistently range from 120 to 129 systolic and less than 80 mm Hg diastolic.

People with elevated blood pressure are at risk of developing high blood pressure unless adequate steps are taken to control it.










Hypertension stage one: At this stage of blood pressure elevation, readings consistently range from 130 to 139 systolic or 80 to 89 mm Hg diastolic.

Doctors at this point could prescribe blood pressure medications and some lifestyle changes to reduce the risk of heart disease and strokes.

Hypertension stage two: During this level, blood pressure readings range consistently from 140/90 mm Hg or higher.

When patients have reached this point of hypertension, medics are very likely to intervene with a combination of medicine and lifestyle changes.

Hypertensive crisis: This is the most critical point blood pressure can reach, and requires urgent medical attention as soon as possible.

When pressure reaches this level, it suddenly exceeds 180/120 mm Hg.

If you have any of the following symptoms, contact an ambulance immediately:

· Shortness of breath

· Chest pain

· Back pain

· Numbness and/or weakness

· Changes in vision

· Difficulty speaking

Eight signs your blood pressure is too high

Hypertension can be terrifying because many people who get it won’t experience any symptoms.

In some cases, it may take years or decades for the condition to reach levels high enough that symptoms become obvious.

Even then, it’s easy to attribute the symptoms to other health ailments, but acting for a symptom of high blood pressure can be fatal so be extra wary if you think you could be affected.

The best way to know if you have hypertension or your blood pressure is too high is to have regular readings, but signs to look out for include:

· Headaches

· Shortness of breath

· Nosebleeds

· Flushing

· Dizziness and nausea

· Chest pains

· Visual changes

· Bleeding in the urine

Booster shots هل سيحتاج الناس إلى جرعة ثالثة؟ الآن يبحثوا الجرعة الثالثة للعاملين بالمجال الطبي وكبار السن!

 حيث أنهم لا يعلمو مدى تحصين اللقاح لإخذه والمدة التي ينتهي فيها التأثير ويعود الشخص عرضة للمرض مره أخرى أو يبدأ في أخذ جرعات من اللقاح جديدة! لتأمين دوام الوقاية تماماً مثل لقاحات الأنفلونزا هنا يتكلموا عن الجرعة الثالثة أو المنشطة !! كذلك سيتم الأعتراف قريباً بأن لقاحات فايزر وموديرنا تسبب في بعض الأشخاص أعراض قد تكون مميتة في عضلة القلب

Booster shots may NOT be needed this autumn but the elderly and NHS will be first in line if they are, claims one of No10's top vaccine advisers 

Booster Covid vaccines may not be needed this autumn, one of the Government's top experts claimed today.

Professor Adam Finn, from the Joint Committee on Vaccination and Immunisation (JCVI) - which advises No10, insisted top-up jabs may well be required for the very elderly and NHS workers.

But he admitted there was still a 'high level of uncertainty' over whether they would be necessary for millions of other Brits.

Scientists had expected the protection given by vaccines to begin to wear off over time but they don't yet know how long immunity from Covid jabs lasts for.

Influenza vaccines are needed every winter because the virus is constantly evolving to beat the human immune system. 

Coronaviruses tend to mutate slower and academics have claimed they've yet to see any proof of waning immunity in vaccinated Britons.

Last month Matt Hancock announced at a Downing St press conference scientists were beginning trials of a third jab to check if it offers better protection.

Millions more vaccine doses than necessary have been bought by the Government and a giant order of 60million more Pfizer doses in April was earmarked for a top-up campaign in the autumn. 

==============================

British health chiefs could soon issue a warning that Pfizer and Moderna's Covid jabs are linked to heart issues in extremely rare cases, experts believe. 

Fears about the two jabs causing myocarditis have grown in recent weeks, following a string of cases in young adults and children in Israel and the US.

American regulators have already accepted there is a 'likely link' between the heart condition and the vaccines, and will add warnings about the potential complication on information sheets given to the public.

Israel's Health Ministry has said the Pfizer vaccine, the only jab it is using in its rollout, is the 'probable' cause in a tiny number of cases. 

Last week the Medicines and Healthcare products Regulatory Agency (MHRA), which polices the safety of drugs in the UK, said rates of myocarditis among vaccinated adults were 'similar or below' expected levels.

But last night, MailOnline can reveal the watchdog dropped all mention of how often the complication was occurring. Instead, it just updated its weekly summary to say cases were 'very rare' and 'typically mild'.

One cardiologist said he believed it the change in tone may signal that the body was going to accept a link between the two vaccines and myocarditis. 

Other experts warned it further complicated the debate about vaccinating children in Britain. 

============================================================

WHAT IS MYOCARDITIS? 

Myocarditis is an inflammation of the heart muscle. There are no specific causes of the condition but it is usually triggered by a virus.

Some of the most common infections which cause myocarditis, are those called adenovirus and Coxsackie B.

It can be caused by the common cold, hepatitis B and C, and herpes simplex virus. 

The most common symptoms of the condition include chest pain, a fever, a fast heartbeat, tiredness and shortness of breath.

If the inflammation damages the heart muscle or the fibres that conduct electrical pulses to the heart, complications can develop.

They can develop quickly, and include sudden loss of consciousness, an abnormally fast, slow or irregular heartbeat.

In very severe cases the condition is fatal, causing heart failure or sudden death. The inflammation enlarges the heart and creates scar tissue, forcing it to work harder and therefore making it weaker.

In most cases of viral myocarditis, the illness goes away and there are no complications. 

But in rare cases when inflammation is severe, there can be damage to the heart which needs monitoring and possibly a heart transplant.

Myocarditis can reoccur, but there is no known way to prevent this. The risk of recurrence is low, around 10 to 15 per cent, according to Myocarditis Foundation.

It is difficult to gauge the prevalence of myocarditis because there is no widely available test for it.

In 2010, approximately 400,000 people died of heart muscle disease - cardiomyopathy that includes myocarditis - worldwide.

Expert consensus opinion estimates that up to 40 per cent of dilated cardiomyopathy results from myocarditis, according to the National Organisation for Rare Disorders.

الموضوع في دايلي ميل

https://www.dailymail.co.uk/news/article-9725051/UK-health-chiefs-say-rates-myocarditis-higher-expected-amoung-young-adults.html

AstraZeneca & Pfizer's jabs some problems (quoted from https://www.dailymail.co.uk/news/article-9712333/

 

Four British men develop potentially deadly Guillain-Barré syndrome just days after having AstraZeneca's Covid jab

• Four men in Nottingham developed Guillain-Barré syndrome after a Covid jab
• Cases linked to AstraZeneca's vaccine but scientists have not identified cause
• Six cases of the syndrome were also identified in Australia and seven in India

Four British men have developed a potentially life-threatening condition just days after having AstraZeneca's Covid vaccine. 

The recipients developed Guillain-Barré syndrome, which can cause paralysis and leave patients in crippling pain. 

All four cases were spotted in the Nottingham area, where around 700,000 people have had the British firm's coronavirus jab. 

British health chiefs have yet to offer a public breakdown of how many cases of the syndrome have been spotted in vaccine recipients across the entire country. 

But a similar link has been spotted in both Australia and India, where AstraZeneca's vaccine is also being dished out. It is also a known rare side effect of flu and HPV jabs.

AstraZeneca's jab — which is given as a double-dose — has also been heavily linked to deadly blood clots in younger adults. 

For that reason, UK drug watchdogs have recommended under-40s, who face a tiny risk of falling seriously ill with Covid, get alternative jabs.

But data is now also emerging that shows Pfizer's jab — the other main option being administered in the UK — may cause heart inflammation. 

Cases of Guillain-Barre syndrome after AstraZeneca's vaccine were described in two separate studies in the journal Annals of Neurology.

The complication — normally triggered by an infection — usually occurs in around one in 100,000 people in the UK and US.

What is Guillain-Barre syndrome?

Guillain–Barré syndrome is a rare disorder in which the immune system goes into overdrive and the body attack its own nerves.

Common symptoms of the rare condition include weakness and tingling in the limbs. 

As patients' conditions worsen, this can lead to parts of the body — or in some cases the whole body — being paralysed.

The syndrome is rare, affecting about one in 100,000 annually in the UK and US.

Fewer than 20,000 cases are diagnosed per year in the US, according to the National Institute of Neurological Disorders and Stroke. 

Doctors say it is often triggered by a viral or bacterial illness, such as Campylobacter jejuni. 

There is no cure. Treatment focuses on restoring the nervous system.

It can be fatal if it involves the respiratory muscles. 

But doctors in India who also uncovered the link say it was occurring up to 10 times more than expected.

One of the articles published in the journal broke down the cases spotted in Nottingham, which all occurred within ten days of each other. 

Symptoms began 11 to 22 days after the first jab and all of the four men were aged between 20 and 57.

One had no relevant medical history. The three others others had ulcerative colitis, asthma and high blood pressure.

None had been infected with Covid. They were treated with antibodies and steroid pills.

Dr Christopher Allen, a clinical neuroscientist at Nottingham University, who wrote the article, admitted they cannot be certain the jab caused the neurological illness and it could have happened by chance.

But it demonstrates the need for 'robust post-vaccination surveillance,' he said. And he added vaccines currently deployed are 'very safe'.

Dr Allen added the reaction may be 'a cross-reactive immune response to the SARS-CoV-2 spike protein', causing the immune system to overreact and the body to attack its own nerves. 

Dr Allen said if the condition is caused by AstraZeneca's vaccine, it will be because spike proteins contained in the firm's viral vector technology.

Pfizer's and Moderna's MRNA vaccines do not contain the same spike proteins, so are unlikely to see similar links to the syndrome.

The second paper by neurologists at the Aster Medcity hospital in Kochi, Kerala, identified seven cases of severe Guillain-Barré syndrome.

They were struck down within a fortnight of receiving the first AstraZeneca vaccine.

Lead author Dr Boby Varkey Maramattom said rates of the condition were between 1.4 and 10-fold higher than would normally be expected. 

And the patients suffered 'unusually severe' facial weakness — one of the symptoms of the condition.

Four of the cases involved women aged 40 to 70 years — three of whom required mechanical ventilation.

Nerve damage around the face and head occurred in four patients — which happens in less than five per cent of Guillain-Barré syndrome cases.

Dr Maramattom said while the findings suggested the vaccine could be to blame a clear link had been proven and it is 'unlikely' the jabs had triggered the syndrome in all cases.

The benefits of vaccination also 'substantially outweigh the risk of this relatively rare outcome,' he said.

Covid itself is also linked to Guillain-Barré syndrome, with the virus believed to have triggered the condition in a man, 54, in New Jersey in April 2020.